R&G PharmaStudies Valuation

Q: What is the Fair Price of 301333 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301333 (CN¥38.8) is trading below our estimate of [[fair value]] (CN¥66.3)

Is 301333 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301333 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301333 (CN¥38.8) is trading below our estimate of fair value (CN¥66.3)

Significantly Below Fair Value: 301333 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301333?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 301333. This is calculated by dividing 301333's market cap by their current preferred multiple.
What is 301333's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥3.92b

301333 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.1x
Enterprise Value/EBITDA	17.6x
PEG Ratio	1x

Price to Earnings Ratio vs Peers

How does 301333's PE Ratio compare to its peers?

The above table shows the PE ratio for 301333 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.5x
688621 Beijing Sun-Novo Pharmaceutical Research	16x	28.1%	CN¥3.6b
688222 HitGen	54.4x	5.0%	CN¥3.6b
301096 Hangzhou Bio-Sincerity Pharma-TechLtd	13.3x	28.7%	CN¥4.0b
688315 Novogene	22.2x	18.9%	CN¥4.2b
301333 R&G PharmaStudies	27.6x	26.7%	CN¥3.9b

Price-To-Earnings vs Peers: 301333 is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the peer average (26.5x).

Price to Earnings Ratio vs Industry

How does 301333's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	26.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 301333 is good value based on its Price-To-Earnings Ratio (27.6x) compared to the Asian Life Sciences industry average (27.7x).

Price to Earnings Ratio vs Fair Ratio

What is 301333's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301333 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	27.6x
Fair PE Ratio	24.6x

Price-To-Earnings vs Fair Ratio: 301333 is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the estimated Fair Price-To-Earnings Ratio (24.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 301333 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥38.80	CN¥55.00 +41.8%	1.8%	CN¥56.00	CN¥54.00	n/a	2
Aug ’25	CN¥46.40	CN¥60.50 +30.4%	7.4%	CN¥65.00	CN¥56.00	n/a	2
Jul ’25	CN¥34.23	CN¥60.50 +76.7%	7.4%	CN¥65.00	CN¥56.00	n/a	2
Jun ’25	CN¥44.49	CN¥60.50 +36.0%	7.4%	CN¥65.00	CN¥56.00	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.